Related Experiment Video
Updated: May 15, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Published on: March 7, 2017
WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas
Viola Caretti1, Lotte Hiddingh, Tonny Lagerweij
1Departments of Pediatric Oncology, VU University Medical Center, Amsterdam, the Netherlands.
Abstract:
Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric disease. Thus far, no therapeutic agent has proven beneficial in the treatment of this malignancy. Therefore, conventional DNA-damaging radiotherapy remains the standard treatment, providing transient neurologic improvement without improving the probability of overall survival. During radiotherapy, WEE1 kinase controls the G(2) cell-cycle checkpoint, allowing for repair of irradiation (IR)-induced DNA damage. Here, we show that WEE1 kinase is one of the highest overexpressed kinases in primary DIPG tissues compared with matching non-neoplastic brain tissues. Inhibition of WEE1 by MK-1775 treatment of DIPG cells inhibited the IR-induced WEE1-mediated phosphorylation of CDC2, resulting in reduced G(2)-M arrest and decreased cell viability. Finally, we show that MK-1775 enhances the radiation response of E98-Fluc-mCherry DIPG mouse xenografts. Altogether, these results show that inhibition of WEE1 kinase in conjunction with radiotherapy holds potential as a therapeutic approach for the treatment of DIPG.
Insights
Diffuse intrinsic pontine glioma (DIPG), a fatal pediatric brain cancer, currently lacks effective treatments. Targeting WEE1 kinase with MK-1775 enhances radiotherapy response, offering a potential new therapeutic strategy for DIPG.
Area of Science:
- Oncology
- Molecular Biology
- Pediatric Medicine
Background:
- Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive and fatal pediatric brain tumor.
- Current treatments, including radiotherapy, offer only transient benefits without improving overall survival.
- WEE1 kinase plays a critical role in DNA damage repair during radiotherapy by controlling the G2 cell-cycle checkpoint.
Purpose of the Study:
- To investigate the role of WEE1 kinase in DIPG.
- To evaluate the efficacy of WEE1 kinase inhibition combined with radiotherapy as a treatment for DIPG.
Main Methods:
- Analysis of WEE1 kinase expression in DIPG tissues.
- Inhibition of WEE1 kinase using the drug MK-1775 in DIPG cell lines.
- Assessment of cell viability and cell-cycle arrest (G2-M) following MK-1775 and irradiation (IR).
- Evaluation of MK-1775 combined with radiotherapy in DIPG mouse xenograft models.
Main Results:
- WEE1 kinase is significantly overexpressed in DIPG tissues compared to normal brain tissue.
- MK-1775 treatment inhibited WEE1-mediated phosphorylation of CDC2, reducing G2-M arrest and decreasing cell viability in DIPG cells exposed to IR.
- Combination therapy with MK-1775 and radiotherapy enhanced tumor response in DIPG mouse xenografts.
Conclusions:
- WEE1 kinase is a potential therapeutic target in DIPG.
- Inhibiting WEE1 kinase with MK-1775 potentiates the anti-cancer effects of radiotherapy.
- Combining WEE1 inhibition with radiotherapy presents a promising therapeutic strategy for treating DIPG.
